Shares of Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) fell 7.6% on Tuesday. The stock traded as low as $18.64 and last traded at $18.13. Approximately 6,571 shares were traded during trading, a decline of 99% from the average session volume of 456,192 shares. The stock had previously closed at $19.62.
Wall Street Analysts Forecast Growth
BRVE has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 price objective on shares of Braveheart Bio in a research report on Tuesday, October 20th. Zacks Research raised shares of Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. Wall Street Zen raised shares of Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings assumed coverage on shares of Braveheart Bio in a report on Monday, November 2nd. They set a “sell (d-)” rating on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 price target on the stock. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Braveheart Bio has a consensus rating of “Moderate Buy” and an average target price of $45.25.
Check Out Our Latest Analysis on Braveheart Bio
Braveheart Bio Stock Performance
The firm has a market capitalization of $1.71 billion and a P/E ratio of -7.57. The stock has a fifty day moving average price of $21.93.
Braveheart Bio (NASDAQ:BRVE – Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.40. As a group, equities research analysts expect that Braveheart Bio, Inc. will post -1.97 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Braveheart Bio stock. Goldman Sachs Group Inc. acquired a new position in shares of Braveheart Bio, Inc. (NASDAQ:BRVE – Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,645 shares of the company’s stock, valued at approximately $841,000.
About Braveheart Bio
We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.
See Also
- Five stocks we like better than Braveheart Bio
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.
